報價延遲最少15分鐘:2025/01/11 17:52 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
56.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.32/-1.22
|
|
企業價值
3.56B
|
| 資產負債 |
|
每股賬面淨值
0.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
77.43M
|
|
每股收益
0.71
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:52 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states. |